‘Textbook Conflict of Interest’: Did Blackstone Pressure FDA to Reverse Course on Moderna mRNA Flu Vaccine?

by Michael Nevradakis, Ph.D.

In February, the U.S. Food and Drug Administration (FDA) made waves after it declined to review the Phase 3 clinical trial data for Moderna’s mRNA flu vaccine. One week later, the FDA reversed course — and by early March, the agency’s vaccines head, Dr. Vinay Prasad, was gone.

The events occurred amid a broader shift away from vaccine-related messaging — by the Trump administration and the “Make America Healthy Again” (MAHA) movement — leading up to this year’s midterm elections.

The messaging shift disappointed many MAHA activists and led the administration to try to shore up MAHA support.

Some analysts have suggested that polls showing lukewarm public support for stricter vaccine policies contributed to the administration’s decision to pivot away from vaccine messaging.

But some medical freedom advocates have questioned those polls. They suggest instead that lobbying by influential investors — specifically, Blackstone — has more to do with the shift in messaging and policy than public opinion…

READ FULL ARTICLE HERE… (childrenshealthdefense.org)

 

---

Home | Caravan to Midnight (zutalk.com) Live Stream + Chat (zutalk.com)

We Need Your Help To Keep Caravan To Midnight Going,

Please Consider Donating To Help Keep Independent Media Independent